Royalty Pharma plc
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Pablo Gerardo Legorreta
- Full Time Employees
- 100
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 110 East 59th Street New York NY United States 10022
- IPO Date
- Jun 16, 2020
- CIK
- 0001802768
- Website
- royaltypharma.com
- Similar Companies
- Business
- Royalty Pharma plc (Nasdaq: RPRX) operates as the world's largest buyer of biopharmaceutical royalties and a leading funder of innovation across the life sciences industry; the company acquires royalties on sales of approved and development-stage biopharmaceutical products from originators including pharmaceutical companies, biotechnology firms, universities and research institutions. Its portfolio encompasses royalties on more than 35 marketed products and over a dozen pipeline candidates targeting diseases such as cystic fibrosis (Kalydeco, Orkambi, Symdeko, Trikafta from Vertex Pharmaceuticals), multiple sclerosis (Tysabri from Biogen, frexalimab from Sanofi), blood cancers (Imbruvica from AbbVie and Johnson & Johnson, IDHIFA from Bristol Myers Squibb), prostate cancer (Xtandi from Astellas and Pfizer, Erleada from Johnson & Johnson), ATTR amyloidosis (Amvuttra from Alnylam), spinal muscular atrophy (Evrysdi from Roche, Spinraza from Biogen), migraine (Emgality from Lilly, Nurtec ODT and Zavzpret from Pfizer), diabetes (Januvia and Onglyza from Merck, Soliqua from Sanofi), inflammatory conditions (Tremfya from Johnson & Johnson, Cimzia from UCB, Entyvio from Takeda), respiratory diseases (Trelegy Ellipta from GSK, Airsupra from AstraZeneca), and other areas including schizophrenia (Cobenfy from Bristol Myers Squibb, TEV-'749 from Teva), growth hormone deficiency (Skytrofa from Ascendis Pharma), bladder cancer (Adstiladrin from Ferring), hypoparathyroidism (Yorvipath from Ascendis), low-grade glioma (Voranigo from Servier), chronic graft-versus-host disease (Niktimvo from Syndax and Incyte), and myelodysplastic syndromes (Rytelo from Geron); pipeline royalties include obexelimab for immunoglobulin G4-related disease from Zenas BioPharma, Imdelltra for small cell lung cancer from Amgen, daraxonrasib for RAS mutant pancreatic cancer from Revolution Medicines, litifilimab for lupus from Biogen, and others such as aficamten, ampreloxetine, ecopipam, olpasiran, pelacarsen, pelabresib, seltorexant, trontinemab, and tulmimetostat. Royalty Pharma conducts its royalty acquisition and funding activities principally in the United States and Europe, with global exposure through its diverse portfolio of international product sales. Founded in 1996 by Pablo Legorreta and Rory B. Riggs and headquartered in New York, New York, the company went public in 2020. Recent developments include the acquisition of a royalty interest in Alnylam's Amvuttra from Blackstone Life Sciences for $310 million in November 2025; a royalty on Amgen's Imdelltra for small cell lung cancer acquired for up to $950 million in 2025; a $2 billion funding arrangement with Revolution Medicines including royalties on daraxonrasib in June 2025; royalties on Rytelo, Niktimvo, Yorvipath, and Voranigo added in 2024; and earlier 2023-2025 transactions such as royalties on obexelimab, litifilimab, Evrysdi, Skytrofa, Adstiladrin, and Cobenfy, reflecting ongoing expansion into oncology, neurology, rare diseases, and synthetic royalty structures.
Company News
Royalty Pharma (RPRX) Upgraded to Buy: What Does It Mean for the Stock?
Royalty Pharma: Unique, Diversified Life Science And Biopharma Pure Play
Royalty Pharma Q3 Earnings Call Highlights
Royalty Pharma plc (RPRX) Q3 2026 Earnings Call Transcript
Compared to Estimates, Royalty Pharma (RPRX) Q3 Earnings: A Look at Key Metrics
Royalty Pharma (RPRX) Q3 Earnings and Revenues Surpass Estimates
Royalty Pharma reports third quarter 2026 results
Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key Metrics
Should You Buy Royalty Pharma Stock Before Nov. 4?
Forget Biotech's Binary Bets: This Dividend Stock Collects Royalties on Blockbusters Instead
3 Reasons Royalty Pharma Is a Dividend Stock You Never Have to Sell
BioAge Labs (NASDAQ:BIOA) and Royalty Pharma (NASDAQ:RPRX) Critical Comparison
Royalty Pharma declares fourth quarter 2026 dividend
Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026
Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again
Eastern Bank Buys 13,843 Shares of Royalty Pharma PLC $RPRX
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
Royalty Pharma (NASDAQ:RPRX) Stock: Insider Christopher Hite Sells 100,000 Shares
Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?